Publication date: Jul 03, 2023
SARS-CoV-2 is associated with broad tissue tropism, a characteristic often determined by the availability of entry receptors on host cells. Here, we show that TMEM106B, a lysosomal transmembrane protein, can serve as an alternative receptor for SARS-CoV-2 entry into angiotensin-converting enzyme 2 (ACE2)-negative cells. Spike substitution E484D increased TMEM106B binding, thereby enhancing TMEM106B-mediated entry. TMEM106B-specific monoclonal antibodies blocked SARS-CoV-2 infection, demonstrating a role of TMEM106B in viral entry. Using X-ray crystallography, cryogenic electron microscopy (cryo-EM), and hydrogen-deuterium exchange mass spectrometry (HDX-MS), we show that the luminal domain (LD) of TMEM106B engages the receptor-binding motif of SARS-CoV-2 spike. Finally, we show that TMEM106B promotes spike-mediated syncytium formation, suggesting a role of TMEM106B in viral fusion. Together, our findings identify an ACE2-independent SARS-CoV-2 infection mechanism that involves cooperative interactions with the receptors heparan sulfate and TMEM106B.
Concepts | Keywords |
---|---|
Antibodies | ACE2-independent entry |
Cryogenic | antibody neutralization |
Crystallography | coronavirus |
Tmem106b | cryo-EM |
Viral | entry receptor |
SARS-CoV-2 | |
TMEM106B |
Semantics
Type | Source | Name |
---|---|---|
disease | IDO | cell |
disease | IDO | host |
drug | DRUGBANK | Angiotensin II |
disease | MESH | SARS-CoV-2 infection |
drug | DRUGBANK | Phenobarbital |